If you choose to give MenB vaccine to a 16-year-old with HIV infection based on shared clinical decision-making, should you use the 2-dose (standard) schedule or the 3-dose (high-risk) schedule?

Either Trumenba (MenB-FHbp) or the Bexsero MenB vaccine brand (MenB-4C) may be used for people with HIV infection. People with HIV infection do not appear to be at higher risk for meningococcal serogroup B disease, and ACIP does not specify use of the 3-dose schedule for people with HIV. Booster doses of MenB are not recommended for people with HIV in the absence of another indication for MenB vaccination.

Penbraya (MenABCWY, Pfizer) is an option for people age 10 years and older only when both MenACWY and MenB (Trumenba) vaccines are due at the same visit and at least 6 months have elapsed since the most recent dose of Penbraya. An adolescent with HIV should receive a 2-dose primary MenACWY series (with the doses given 8 weeks apart), followed by MenACWY booster doses every 5 years. If this teen needs the MenACWY primary series vaccination and also chooses to receive Trumenba, Penbraya may only be used for one of the doses because dose 2 in the MenACWY primary series is due 8 weeks after dose 1 and the minimum interval between Penbraya doses is 6 months.